Compounded GLP-1s vs. brand-name drugs: what the evidence says

What's this video probably claiming?

Based on the caption linking directly to the Obesity Action Coalition's position paper on compounded GLP-1 alternatives, this creator, who appears to be a physician practicing in Alabama and/or Texas, is likely weighing in on the FDA shortage debate around compounded semaglutide and tirzepatide. The video probably argues that compounded versions of these drugs represent a legitimate, accessible option for patients who can't afford or access brand-name Wegovy, Zepbound, or Mounjaro. The hashtag stack, heavy with brand names, suggests the creator is either defending compounded GLP-1s or explaining the regulatory tension around them. Physicians in states like Texas and Alabama have been particularly vocal on this topic as FDA shortage designations have shifted, affecting whether compounding pharmacies can legally produce these drugs at all. This is a genuinely complicated regulatory and clinical conversation, and the OAC paper is a real, credentialed document worth examining.

What does the science actually show?

The clinical evidence for semaglutide and tirzepatide as branded formulations is strong. The STEP 1 trial (Wilding et al., 2021, NEJM) showed 2.4 mg subcutaneous semaglutide producing around 14.9% mean body weight loss over 68 weeks versus 2.4% for placebo. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) found tirzepatide at 15 mg achieving up to 22.5% body weight reduction over 72 weeks. These are large, well-controlled trials using pharmaceutical-grade compounds manufactured under strict GMP conditions. The problem is that compounded versions of these molecules have not been tested in equivalent trials. The FDA has been explicit: compounded drugs are not FDA-approved and have not undergone the same safety and efficacy review. Salt-form discrepancies, particularly semaglutide sodium versus semaglutide base, add a layer of uncertainty that the clinical data simply does not resolve.

Where does the social media noise diverge from clinical reality?

The loudest claim circulating on TikTok is that compounded semaglutide and tirzepatide are essentially the same drug at a lower price. That framing is misleading, and it matters clinically. The FDA issued a specific warning in 2023 noting that compounded drugs using semaglutide salts are not the same as the active ingredient in Ozempic or Wegovy. Independent testing by organizations like the US Pharmacopeia and reporting from outlets including STAT News have flagged variable potency and sterility concerns in compounded formulations from some 503A and 503B pharmacies. None of this means every compounded product is dangerous, but the blanket equivalency claim that floats across health TikTok ignores real manufacturing variance. Separately, the OAC position paper the creator links to does not endorse compounded GLP-1s as equivalent to brand-name drugs; it advocates for access and calls for clearer regulatory guidance, which is a meaningfully different position.

What should you actually know?

The shortage designation is the legal hinge for everything here. Under 503A and 503B compounding rules, pharmacies can legally produce copies of drugs on the FDA shortage list. Tirzepatide was removed from shortage status by the FDA in March 2024, and semaglutide followed in early 2025, which is why compounding pharmacies have faced enforcement actions. Patients who started compounded GLP-1 therapy may find access disrupted, and clinicians need to have informed conversations about what transition to branded products, or discontinuation, actually looks like physiologically. Weight regain data from the STEP 1 extension (Wilding et al., 2022, Diabetes Care) showed participants regaining roughly two-thirds of lost weight within a year of stopping. That context, not just the cost conversation, belongs in any honest discussion of GLP-1 access.